Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ambrx Inks Three-Target Deal With Wyeth To Develop Antibody-Toxin Conjugates

This article was originally published in The Pink Sheet Daily

Executive Summary

First license deal for Ambrx's EuCode technology offers potential for "silver bullet" therapeutics that localize pharmacologic activity.

You may also be interested in...

Ambrx Links Its ADC Technology To Japan’s Astellas In Oncology Deal

The San Diego biotech has landed another large pharma partner for its antibody-drug conjugation technology as the space continues to attract interest.

Merck, Ambrx Partner In Effort To Create Better-Targeted Drug Conjugates

Unlike most work in antibody-drug conjugates, however, the collaboration will not focus on oncology but on a broad array of undisclosed targets that may be applicable in a wide variety of indications.

Bristol And Ambrx To Collaborate On Preclinical Assets For Type 2 Diabetes, Heart Failure

Bristol's second "String of Pearls" transaction in as many days includes a $24 million upfront payment to privately held Ambrx.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts